Cumberland Pharmaceuticals (NASDAQ:CPIX) Research Coverage Started at StockNews.com

StockNews.com assumed coverage on shares of Cumberland Pharmaceuticals (NASDAQ:CPIX) in a research report released on Tuesday morning. The firm issued a hold rating on the specialty pharmaceutical company’s stock.

Cumberland Pharmaceuticals Trading Down 4.6 %

Shares of CPIX stock opened at $2.50 on Tuesday. The company has a market capitalization of $35.10 million, a price-to-earnings ratio of -3.25 and a beta of 0.13. The company has a current ratio of 1.13, a quick ratio of 0.99 and a debt-to-equity ratio of 0.41. The firm has a 50-day moving average price of $1.98 and a 200 day moving average price of $1.55. Cumberland Pharmaceuticals has a twelve month low of $1.04 and a twelve month high of $3.93.

Cumberland Pharmaceuticals (NASDAQ:CPIX) last issued its quarterly earnings results on Thursday, November 7th. The specialty pharmaceutical company reported ($0.03) EPS for the quarter. Cumberland Pharmaceuticals had a negative return on equity of 9.50% and a negative net margin of 29.54%. The firm had revenue of $9.09 million for the quarter.

Cumberland Pharmaceuticals Company Profile

Cumberland Pharmaceuticals Inc, a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; Sancuso, an injection for the treatment of chemotherapy treatment; and Vibativ, an injection for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections.